Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

NCT05884320 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gland
Salivary Gland Cancers

Interventions

DRUG: Sacituzumab Govitecan

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]